Maynard Um
-
-
-
-
-
-
-
Ocular Therapeutix (OCUL) Reiterated at Market Outperform by Citizens Ahead of Q2 Earnings
-
-
-
-
-
-
-
Ocular Therapeutix enrolls first patient in SOL-X extension trial
-
-
-
-
-
-
-
Ocular Therapeutix (OCUL) PT Raised to $28 at Clear Street
-
-
-
-
-
-
-
Ocular Therapeutix jumps on report Sanofi preparing revised bid
-
-
-
-
-
-
-
Ocular Therapeutix plans to accelerate AXPAXLI submission for wet AMD
-
-
-
-
-
-
-
Ocular Therapeutix (OCUL) PT Raised to $20 at TD Cowen
-
-
-
-
-
-
-
Ocular Therapeutix gets FDA agreement for AXPAXLI diabetic eye trial
-
468,601 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


